PMID: 9417158Jan 17, 1998Paper

alpha1-Proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity: a randomized, controlled trial

Pediatrics
J A StiskalMarlene Rabinovitch

Abstract

An imbalance between increased neutrophil elastase and a decreased antiprotease shield has been suggested as a factor contributing to the development of chronic lung disease (CLD). We hypothesized that administration of alpha1-proteinase inhibitor (A1PI), also known as alpha1-antitrypsin, to premature neonates would prevent CLD. A randomized, placebo-controlled, prospective study of A1PI supplementation was performed. Neonates <24 hours of age with birth weights 600-1000 g on respiratory support, and 1001-1250 g with respiratory distress syndrome (RDS) were eligible. Intravenous A1PI (60 mg/kg) or placebo was infused on days 0, 4, 7, and 14. Primary outcome was CLD in survivors, defined as the need for supplemental oxygen on day 28. A total of 106 patients were recruited. There were no significant differences between groups in birth weight or incidence of RDS. The incidence of CLD in survivors was lower in the treated group, but the difference did not reach statistical significance (relative risk [RR], 0.79; confidence interval [CI], 0.60-1.02). This beneficial trend persisted at 36 weeks corrected gestational age (RR, 0.48; CI, 0.23-1.00). The incidence of pulmonary hemorrhage was lower in the treated group (RR, 0.22; CI, 0.05...Continue Reading

Citations

Apr 12, 2003·Critical Care Medicine·Theo J MoraesGregory P Downey
Apr 1, 2005·Current Opinion in Pediatrics·Linda J Van Marter
Jun 14, 2006·Archives of Disease in Childhood. Fetal and Neonatal Edition·E S ShinwellB Reichman
Feb 16, 2005·Annual Review of Physiology·Kurt R Stenmark, Steven H Abman
Jun 12, 2012·American Journal of Physiology. Lung Cellular and Molecular Physiology·Anne HilgendorffRichard D Bland
Jun 13, 2001·American Journal of Respiratory and Critical Care Medicine·A H Jobe, E Bancalari
May 13, 2011·American Journal of Respiratory and Critical Care Medicine·Anne HilgendorffRichard D Bland
Sep 3, 2011·American Journal of Respiratory and Critical Care Medicine·Rory E Morty
Oct 22, 2005·Journal of Perinatal Medicine·Robert MittendorfPeter G Pryde
Sep 3, 2005·Treatments in Respiratory Medicine·David G Sweet, Henry L Halliday
Sep 4, 2008·Expert Opinion on Emerging Drugs·Anne Greenough
Jul 31, 2007·Expert Opinion on Pharmacotherapy·William E Truog
Jun 1, 2000·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·D G Sweet, H L Halliday
Jul 25, 2006·Seminars in Perinatology·Rajiv Baveja, Helen Christou
Jan 12, 2001·Seminars in Perinatology·C H Cole, J M Fiascone
May 8, 2014·The Journal of Maternal-fetal & Neonatal Medicine : the Official Journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians·Sayako IkedaMadoka Furuhashi
Apr 28, 2005·Journal of Intensive Care Medicine·Helen Christou, Dara Brodsky
Dec 17, 2008·Journal of Perinatology : Official Journal of the California Perinatal Association·D J Askew, G A Silverman
Nov 1, 2001·The Cochrane Database of Systematic Reviews·P Shah, A Ohlsson
Feb 13, 2007·American Journal of Physiology. Lung Cellular and Molecular Physiology·Richard D BlandKeith S K Fong
Jul 3, 2015·American Journal of Physiology. Lung Cellular and Molecular Physiology·Azhar MasoodA Keith Tanswell
Jun 13, 2018·American Journal of Respiratory Cell and Molecular Biology·Miguel A Alejandre AlcazarRichard D Bland

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.